Cancer care saves lives. However, there is mounting evidence that many cancer therapies may cause cardiotoxicity–a condition that damages the heart. As a result, new cancer patients and survivors may be at an increased risk of developing cardiovascular disease.[1]
MyoStrain® provides actionable information to help cardio-oncologists proactively detect and manage the cardiotoxic effects of cancer therapy on the heart without interrupting cancer care. Physicians may be able to use this approach to determine cardio-protective treatment strategies, optimize the effectiveness of protective treatment, and monitor the patient’s heart health throughout cancer therapy.
There are 17 million cancer survivors in the United States, many of whom may not currently be monitored for cardiotoxicity.[2] 30-40% of cancer patients will suffer from progressive heart disease, and 1 in 10 of these patients will experience an adverse cardiac event.[1] Moreover, cancer recurrence is 59% more likely in patients with cardiovascular disease.[3] This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.
MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.
There are 17 million cancer survivors in the United States, many of whom may not currently be monitored for cardiotoxicity.[2] 30-40% of cancer patients will suffer from progressive heart disease, and 1 in 10 of these patients will experience an adverse cardiac event.[1] Moreover, cancer recurrence is 59% more likely in patients with cardiovascular disease.[3] This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.
MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.
There are 17 million cancer survivors in the United States, many of whom may not currently be monitored for cardiotoxicity.[2] 30-40% of cancer patients will suffer from progressive heart disease, and 1 in 10 of these patients will experience an adverse cardiac event.[1] Moreover, cancer recurrence is 59% more likely in patients with cardiovascular disease.[3] This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.
MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.
[1] European Society of Cardiology (2019). Cancer patients are at higher risk of dying from heart disease and stroke. https://www.escardio.org/The-ESC/Press-Office/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke. [2] American Cancer Society (2019). Population of US Cancer Survivors Grows to Nearly 17 Million. https://www.cancer.org/latest-news/population-of-us-cancer-survivors-grows-to-nearly-17-million.html. [3] Bankhead, C. (2020). MI May Fuel Breast Cancer Recurrence, Mortality. Medpage Today. https://www.medpagetoday.com/hematologyoncology/breastcancer/87603?vpass=1.
